Gilead Sciences, Inc. (NASDAQ:GILD) Shareholders to Collect $0.82 Quarterly Dividend

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Thursday, October 29th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share by the biopharmaceutical company on Wednesday, December 30th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th.

Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $9.94 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.0%.

Gilead Sciences Trading Up 4.0%

NASDAQ GILD opened at $165.61 on Friday. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $165.70. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a market cap of $205.35 billion, a price-to-earnings ratio of -62.03 and a beta of 0.31. The firm’s 50 day moving average price is $150.33 and its two-hundred day moving average price is $139.55.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.47 EPS. Equities analysts anticipate that Gilead Sciences will post -0.48 EPS for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Gilead reported non-GAAP EPS of $2.55, above the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion versus expectations of approximately $7.81 billion. Gilead Sciences third-quarter earnings report
• Positive Sentiment: HIV medicines drove the performance. The company highlighted 16% growth in its base business, led by the Biktarvy HIV franchise, while cancer drug Trodelvy also contributed to sales growth. The results represent Gilead’s strongest sales growth in roughly a decade. Gilead HIV franchise earnings report
• Positive Sentiment: Full-year sales guidance was raised. Gilead now expects 2026 product sales of $31.0 billion to $31.3 billion, up from its previous range of $30.1 billion to $30.4 billion and modestly above Wall Street’s expectations. Gilead raises sales guidance
• Positive Sentiment: The quarterly dividend was maintained. Gilead declared an $0.82-per-share quarterly dividend, or $3.28 annualized, representing an approximately 2% yield based on the provided share price. The dividend is payable December 30 to shareholders of record December 15.
• Neutral Sentiment: Analyst reaction was mixed. Robert W. Baird assigned the shares a Hold rating, suggesting the strong operating results may be balanced by valuation near record levels and uncertainty surrounding the company’s pipeline and future growth.
• Negative Sentiment: Profitability and pricing risks temper the report. Gilead widened its 2026 non-GAAP loss forecast, while Medicare-related changes are expected to reduce Biktarvy’s price by 38% beginning in 2028. These factors could pressure future earnings despite the current sales momentum. Gilead Biktarvy pricing and sales outlook

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.